The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2026
    • JPSW 2025
    • JPSW 2024
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Fact or Fallacy
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • AI Writing Policy
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • Contact
    • Editorial Advisory Committee

Fact or Fallacy: Risk of Delirium with Benzodiazepines in Critically Ill Adult Patients

by Meagan Macalalag, PharmD, Jeffrey Fish, PharmD, BCCCP, FCCM

Question: What is the risk of delirium with benzodiazepines in critically ill adult patients?

Delirium is a common and serious complication of critical illness, associated with prolonged hospitalization and long-term cognitive impairment. Benzodiazepines have long been identified as a potentially modifiable risk factor for ICU delirium, leading to guideline recommendations that favor non-benzodiazepine sedatives for many mechanically ventilated patients.

This article critically evaluates the evidence behind the presumed relationship between benzodiazepine exposure and delirium in critically ill adults. While observational studies and select randomized trials suggest an association, the authors highlight important limitations related to sedation depth, timing and frequency of delirium assessments, crossover between treatment groups, and the difficulty of separating residual sedation from delirium. Current evidence does not establish a strong causal relationship between benzodiazepines and delirium. Non-benzodiazepine sedatives remain a reasonable first-line approach for many mechanically ventilated patients, but benzodiazepines may still have an appropriate role in select clinical situations, including anxiety, alcohol withdrawal, and seizure management.

​​
Download PDF

2026 July/August Table of Contents

The Journal of the Pharmacy Society of Wisconsin (ISSN 2837-8229)


Past Issues

2026

2025
2024
2
023
2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

[email protected]
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2026
    • JPSW 2025
    • JPSW 2024
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Fact or Fallacy
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • AI Writing Policy
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • Contact
    • Editorial Advisory Committee